Serum from patients with chest pain and significant atherosclerosis resulted in macrophage cholesterol accumulation
Article Sidebar
Main Article Content
Abstract
Aims: The aim of our study was to analyze the effect of serum derived from patients with chest pain, with or without significant atherosclerosis, on J774A.1 macrophages cholesterol metabolism.
Methods: Thirty-nine patients with chest pain underwent CT Coronary Angiography (CTCA) to assess atherosclerosis. They were divided into three groups (n=13 for each group), according to extent of Coronary Artery Disease (CAD): No disease (NCAD), Non-significant (NSCAD), or significant CAD (SCAD).
Results: Serum total cholesterol level was similar in all three groups, whereas the SCAD group had the lowest serum HDL level and highest serum triglyceride levels, compared with the other groups.
The patient’s serum (30µl) was incubated with J774 macrophages for 18h. Cellular cholesterol mass was found to be significantly higher by 44 percent in SCAD patients compared to NCAD patients, and by 23 percent compared to NSCAD patients.
In parallel, we observed a significant enhanced cholesterol biosynthesis rate by 53 percent in macrophages treated with serum from the SCAD patients, as compared to NCAD patients, or by 17 percent when compared to the NSCAD patients.
In accordance with the above results, HMGCR (the rate limiting enzyme in cholesterol biosynthesis) expression was significantly upregulated in macrophages treated with serum from SCAD patients, in comparison to NCAD or NSCAD patients.
Conclusion: These results clearly demonstrate high macrophage atherogenicity for serum harvested from patients with significant atherosclerosis.
Downloads
Article Details
Copyright (c) 2020 Dawood M, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Libby P (2002) Inflammation in atherosclerosis. Nature 420: 868–874. Link: https://go.nature.com/3iYPQ0n
Xu L, Dai Perrard X, Perrard JL, Yang D, Xiao X, et al. (2015) Foamy monocytes form early and contribute to nascent atherosclerosis in mice with hypercholesterolemia. Arterioscler Thromb Vasc Biol 35: 1787-1797. Link: https://bit.ly/30aC41R
Aviram M, Rosenblat M (2004) Paraoxonases. 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 37: 1304-1316. Link: https://bit.ly/38SmZWO
Ghattas A, Griffiths HR, Devitt A, Lip GY, Shantsila E (2013) Monocytes in coronary artery disease and atherosclerosis: where are we now? J Am Coll Cardiol 62: 1541-1551. Link: https://bit.ly/2AWmFdb
Meuwissen M, van der Wal AC, Nisesen HW, et al. (2006) Colocalisation of intraplaque C reactive protein, complement, oxidized low density lipoprotein, and macrophages in stable and unstable angina and acute myocardial infarction. J Clin Pathol 59: 196-201. Link: https://bit.ly/32fCUxh
Anselmi M, Garbin U, Agostoni P, Fusaro M, Pasini AF, et al. (2006) Plasma levels of oxidized-low-density lipoproteins are higher in patients with unstable angina and correlated with angiographic coronary complex plaques. Atherosclerosis 185: 114-120. Link: https://bit.ly/2AXaFrV
Rom O, Aviram M (2016) Endogenous or exogenous antioxidants vs.pro-oxidants in macrophage atherogenicity. Curr Opin Lipidol 27: 204-206. Link: https://bit.ly/307o219
Aviram M, Rosenblat M, Gaitini D, Nitecki S, Hoffman A, et al. (2004) Pomegranate juice consumption for 3 years by patients with carotid artery stenosis reduces common carotid intima-media thickness, blood pressure and LDL oxidation. Clin Nutr 23: 423-433. Link: https://bit.ly/38VWDDb
Castelli WP (1988) Cholesterol and lipids in the risk of coronary artery disease—the Framingham Heart Study. Can J Cardiol 4: 5A–10A. Link: https://bit.ly/2OjZEnu
Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, et al. (2007) HDL cholesterol, very low levels of LDL cholesterol and cardiovascular events. N Engl J Med 357: 1301-1310. Link: https://bit.ly/3gZHCU2
Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA (2010) The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res 51: 2058–2073. Link: https://bit.ly/3fuOEiY
Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic R, et al. (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomization study. Lancet 380: 572-580. Link: https://bit.ly/2WxXuFx
Chazov El, Tertov VV, Orckhov AN, Lyakishev AA, Perova NV, et al. (1986) Atherogenicity of blood serum from patients with coronary heart disease. Lancet 2: 595-598. Link: https://bit.ly/2Wjs2KK
Orekhov AN, Tertov VV, Pokrovsky SN, IYu A, Martsenyuk, et al. (1988) Blood serum atherogenicity associated with coronary atherosclerosis. Evidence for nonlipid factor providing atherogenicity of low-density lipoproteins and an approach to its elimination. Circ Res 62: 421-429. Link: https://bit.ly/2ZoNfVy
Sobenin IA, Chistiakov DA, Bobryshev YV, Orekhov AN (2013) Blood atherogenicity as a target for anti-atherosclerotic therapy. Curr Pharm Des 19: 5954-5962. Link: https://bit.ly/2Ok9cyZ
Dancy L, O'Gallagher K, Milton P, Sado D (2018) New NICE guidelines for the management of stable angina. Br J Gen Pract 68: 202–203. Link: https://bit.ly/2WhoIQk
Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275. Link: https://bit.ly/2WkAxWa
Zhaou C, Lei H, Chen Y, Liu Q, Li LC, et al. (2013) Enhanced SCAP glycosylation by inflammation induces macrophage foam cell formation. Plos One 8: e75650. Link: https://bit.ly/38U07pM
Igor AS, Veronica AM, Elena VA, Pavlova XN, Möhlenkamp S, et al. (2014) Blood serum atherogenicity and coronary artery calcification. Curr Pharm Des 20: 5884–5888. Link: https://bit.ly/3iZCjp7
Tan JME, Cook ECL, van den Berg M, Scheij S, Zelcer N, et al. (2019) Differential use of E2 ubiquitin conjugating enzymes for regulated degradation of the rate-limiting enzymes HMGCR and SQLE in cholesterol biosynthesis. Atherosclerosis 281: 137-142. Link: https://bit.ly/308rlFh
Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, et al. (2011) Cholesterol efflux capacity, high-density lipoprotein function and atherosclerosis. N Engl J Med 364: 127-135. Link: https://bit.ly/3ft1bUj
Sini S, Deepa D, Harikrishnan S, Jayakumari N (2017) High-density lipoprotein from subjects with coronary artery disease promotes macrophage foam cell formation: role of scavenger receptor CD36 and ERK/MAPK signaling. Mol Cell Biochem 427: 23-34. Link: https://bit.ly/3ftWvgN
Sini S, Deepa D, Harikrishnan S, Jayakumari N (2018) Adverse effects on macrophage lipid transport and survival by high density lipoprotein from patients with coronary heart disease. J Biochem Mol Toxicol 32: e22192. Link: https://bit.ly/38UsdRT
Norimatsu K, Kuwano T, Miura SI, Shimizu T, Shiga Y, et al. (2017) Significance of the percentage of cholesterol t efflux capacity and total cholesterol efflux capacity in patients with or without coronary artery disease. Heart Vessels 32: 30-38. Link: https://bit.ly/38VDW2Q
Huff MW, Evans AJ, Sawyez CG, Wolfe BM, Nestel PJ (1991) Cholesterol accumulation in J774 macrophages induced by triglyceride-rich lipoproteins. Comparison of very low density lipoprotein from subjects with type III, IV and V hyperlipoproteinemias. Arterioscler Throm 11: 221-233. Link: https://bit.ly/304WJVm
Georgopoulos A, Kafonek SD, Raikhel I (1994) Diabetic postprandial triglyceride-rich lipoproteins increase esterified cholesterol accumulation in THP-1 macrophages. Metabolism 43: 1063-1072. Link: https://bit.ly/3iZSfb8